Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. Class H

As of December 31, 2025, Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. Class H carries a market capitalization of 1.86B, placing it among publicly traded companies globally. Its enterprise value stands at 1.24B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of December 31, 2025, Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. Class H has 245.40M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. Class H maintains a current ratio of 4.46, meaning it holds 4.5x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 22, 2026, Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. Class H's stock has declined approximately 40.10% over the past 52 weeks. The 50-day moving average sits at 5.39, while the 200-day moving average is 6.87.

As of December 31, 2025, Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. Class H holds 795.12M in cash and equivalents against 179.86M in total debt, resulting in a net debt position of -273.90M. Total book value stands at 1.83B, with working capital of 1.28B providing operational flexibility.